Inclusion Criteria:

          -  Evaluate safety and tolerability of the combination of ADT and docetaxel for up to
             three months following the last dose of docetaxel.

          -  High risk prostate cancer defined as extracapsular extension (cT3a) or seminal vesicle
             involvement (cT3b) or invasion of adjacent structures (cT4), serum PSA >20 ng/mL or
             Gleason score of 8 to 10 and/or regional lymph node or

          -  Oligometastatic disease defined as disseminated metastases beyond regional lymph nodes
             that meet the following criteria:

               -  No visceral metastases

               -  Less than four bony metastases.

          -  Ability to comply with all study procedures and willingness to remain supine for 120
             minutes during imaging.

          -  Patients must be informed of the experimental nature of the study and its potential
             risks, and must sign an Institutional Review Board (IRB)-approved written informed
             consent form indicating such an understanding.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.

          -  Patients must be considered candidates for prostatectomy as per standard of care.

          -  Adequate hematologic and renal function as evidenced by the following within 4 weeks
             of day 1:

               -  ANC >1500/mm3

               -  Hemoglobin (HgB) >10.0 gr/dL independent of transfusion

               -  Platelets >100,000/mm3

               -  Creatinine <2.0 mg/dL

               -  Total bilirubin < Upper Limit of Normal (ULN)

          -  Estimated life expectancy of ≥ 12 months at screening.

          -  Throughout the study, patient and his female partner who is of childbearing potential
             must use 2 acceptable methods of birth control (1 of which must include a condom as a
             barrier method of contraception) from screening through 3 months after last dose of
             study drug. Two acceptable methods of birth control thus include the following:

               -  A condom (barrier method of contraception) AND One of the following is required:

               -  Established and ongoing use of oral, injected, or implanted hormonal method of
                  contraception by the female partner

               -  Placement of an intrauterine device or intrauterine system by the female partner

               -  Additional barrier method: Contraceptive sponge or occlusive cap (diaphragm or
                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the
                  female partner

               -  Tubal ligation in the female partner performed at least 6 months before screening

               -  Vasectomy or other procedure resulting in infertility (eg, bilateral
                  orchiectomy), performed at least 6 months before screening

          -  While receiving chemotherapy, the patient must use a condom if having sex with a
             pregnant woman.

          -  Must agree not to donate sperm from first dose of study drug through 3 months after
             the last dose of study drug.

        Exclusion Criteria:

          -  Prior treatment for prostate cancer, including ADT, orchiectomy, antiandrogens,
             ketoconazole, abiraterone acetate or enzalutamide.

          -  Prior radiation to the prostate.

          -  Use of other investigational agent for prostate cancer.

          -  No active secondary malignancy

          -  Chronic liver disease or abnormal liver function:

               -  Total bilirubin >ULN (NOTE: in subjects with Gilbert's syndrome, if total
                  bilirubin is >ULN, measure direct and indirect bilirubin and if direct bilirubin
                  is within normal range, subject may be eligible) or

               -  Alanine (ALT) or aspartate (AST) aminotransferase >2.0 x ULN or

               -  ALT or aspartate AST >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN.

          -  Peripheral neuropathy grade >1.

          -  Active cardiac disease defined as active angina, symptomatic congestive heart failure,
             or myocardial infarction within the previous 6 months.

          -  Major surgery within 4 weeks before screening.

          -  Patients with known psychological or sociological conditions, addictive disorders or
             family problems, which would preclude compliance with the protocol.

          -  Herbal supplements that have been shown to modulate testosterone or androgen signaling
             (e.g. Saw Palmetto) are not allowed while on study.

          -  Subjects may not be enrolled concurrently on other treatment studies. Any concurrent
             disease, infection, or comorbid condition that interferes with the ability of the
             patient to participate in the trial; places the patient at undue risk; or complicates
             the interpretation of the data, in the opinion of the investigator or medical monitor.

          -  Subjects who will be receiving Ferumoxytol MRI tracer must:

               -  Not have any known hypersensitivity to Feraheme or any of its components

               -  Must not have a history of allergic reaction to any intravenous iron product.

               -  Must not have a known iron overload (based on medical history)